For patients with positive CMs, including carcinoma in situ, EIC (P <0.001) and BC subtypes (HER-2 vs. luminal A: P <0.001; luminal B vs. luminal A: P = 0.008; luminal-HER-2 vs. luminal A: P = 0.032, Table 4) showed a significant association with positive CMs. Here, ERBB2 is linked to in situ carcinoma.